http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 12:09:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26927634.html si-local-file:///var/storage/secattach/20260814/26927634.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26927634.html Fri, 14 Aug 2026 12:09:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26927634.html si-local-file:///var/storage/secattach/20260814/26927634.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26927634.html Fri, 14 Aug 2026 12:09:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926600.html si-local-file:///var/storage/secattach/20260814/26926600.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926600.html Fri, 14 Aug 2026 10:39:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926600.html si-local-file:///var/storage/secattach/20260814/26926600.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926600.html Fri, 14 Aug 2026 10:39:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%2453+at+Barclays/26886488.html Barclays analyst Etzer Darout raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $53.00 (from $48.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%2453+at+Barclays/26886488.html Fri, 07 Aug 2026 04:53:38 -0400 CLDX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Celldex+Therapeutics%2C+++++For%3A+Jun+30/26883737.html si-local-file:///var/storage/secattach/20260806/26883737.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Celldex+Therapeutics%2C+++++For%3A+Jun+30/26883737.html Thu, 06 Aug 2026 16:07:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Celldex+Therapeutics%2C+++++For%3A+Jun+30/26883737.html si-local-file:///var/storage/secattach/20260806/26883737.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Celldex+Therapeutics%2C+++++For%3A+Jun+30/26883737.html Thu, 06 Aug 2026 16:07:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Earnings/Celldex+%28CLDX%29+Tops+Q2+EPS+by+12c/26883456.html <p>Celldex (NASDAQ: CLDX) reported Q2 EPS of ($0.94), $0.12 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $22 thousand versus the consensus estimate of $802.64 thousand.</p><p>For earnings history and earnings-related data on Celldex (CLDX) <a href="http://www.streetinsider.com/ec_earnings.php?q=CLDX">click here</a>.</p> http://www.streetinsider.com/Earnings/Celldex+%28CLDX%29+Tops+Q2+EPS+by+12c/26883456.html Thu, 06 Aug 2026 16:05:09 -0400 CLDX http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celldex+Therapeutics%2C+++++For%3A+Aug+06/26883313.html si-local-file:///var/storage/secattach/20260806/26883313.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celldex+Therapeutics%2C+++++For%3A+Aug+06/26883313.html Thu, 06 Aug 2026 16:01:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celldex+Therapeutics%2C+++++For%3A+Aug+06/26883313.html si-local-file:///var/storage/secattach/20260806/26883313.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celldex+Therapeutics%2C+++++For%3A+Aug+06/26883313.html Thu, 06 Aug 2026 16:01:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%2472+at+Wells+Fargo/26831051.html Wells Fargo analyst Derek Archila raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $72.00 (from $48.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%2472+at+Wells+Fargo/26831051.html Wed, 29 Jul 2026 08:13:26 -0400 CLDX http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2440+at+Morgan+Stanley/26798693.html Morgan Stanley analyst Judah Frommer lowered the price target on Celldex Therapeutics (NASDAQ: CLDX) to $40.00 (from $44.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2440+at+Morgan+Stanley/26798693.html Wed, 22 Jul 2026 08:25:48 -0400 CLDX http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2460+at+Canaccord/26797843.html (Updated - July 22, 2026 7:41 AM EDT) <p>Canaccord analyst Ed Nash lowered the price target on Celldex Therapeutics (NASDAQ: CLDX) to $60.00 (from $62.00) while maintaining a Buy rating.</p><p>The analyst commented: "Today after the market close, Celldex reported that the Phase II study for barzolvolimab in PN missed on the primary and key secondary efficacy endpoints with no difference demonstrated in the treatment group vs. PBO. The company is discontinuing the PN program. To reflect this update, we have zeroed out the PN program from our valuation and are lowing our 12-month PT from the prior $62 to $60. We http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Lowered+to+%2460+at+Canaccord/26797843.html Wed, 22 Jul 2026 07:41:24 -0400 CLDX